Characterization of the genotype and integration patterns of hepatitis B virus in early‐ and late‐onset hepatocellular carcinoma

Hongli Yan, Yuan Yang, Ling Zhang, Guannan Tang, YuZhao Wang, Geng Xue, Weiping Zhou, Shuhan Sun – 27 January 2015 – Early‐onset hepatocellular carcinoma (HCC) accounts for 15%‐20% of total HCC cases in Asia, and the incidence is increasing. The low frequency of cirrhosis and poor prognosis of early‐onset HCC suggests that its mechanisms may differ from late‐onset HCC. Although hepatitis B virus (HBV) infection is epidemiologically associated with HCC, the role of HBV in early‐onset HCC remains poorly understood.

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014

Natalie J. Torok, Jonathan A. Dranoff, Detlef Schuppan, Scott L. Friedman – 27 January 2015 – There is an urgent need to develop antifibrotic therapies for chronic liver disease, and clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. The American Association for the Study of Liver Diseases sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and develop recommendations on clinical trial design for liver fibrosis.

Interaction of tetraspan(in) TM4SF5 with CD44 promotes self‐renewal and circulating capacities of hepatocarcinoma cells

Doohyung Lee, Juri Na, Jihye Ryu, Hye‐Jin Kim, Seo Hee Nam, Minkyung Kang, Jae Woo Jung, Mi‐Sook Lee, Haeng Eun Song, Jungeun Choi, Gyu‐Ho Lee, Tai Young Kim, June‐Key Chung, Ki Hun Park, Sung‐Hak Kim, Hyunggee Kim, Howon Seo, Pilhan Kim, Hyewon Youn, Jung Weon Lee – 27 January 2015 – Tumor metastasis involves circulating and tumor‐initiating capacities of metastatic cancer cells. Epithelial‐mesenchymal transition (EMT) is related to self‐renewal capacity and circulating tumor cell (CTC) characteristics for tumor metastasis.

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014

Natalie J. Torok, Jonathan A. Dranoff, Detlef Schuppan, Scott L. Friedman – 27 January 2015 – There is an urgent need to develop antifibrotic therapies for chronic liver disease, and clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. The American Association for the Study of Liver Diseases sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and develop recommendations on clinical trial design for liver fibrosis.

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob P. Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley F. Freilich, Ziad H. Younes, William Harlan, Reem Ghalib, Godson Oguchi, Paul J. Thuluvath, Grisell Ortiz‐Lasanta, Mordechai Rabinovitz, David Bernstein, Michael Bennett, Trevor Hawkins, Natarajan Ravendhran, Aasim M. Sheikh, Peter Varunok, Kris V. Kowdley, Delphine Hennicken, Fiona McPhee, Khurram Rana, Eric A.

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob P. Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley F. Freilich, Ziad H. Younes, William Harlan, Reem Ghalib, Godson Oguchi, Paul J. Thuluvath, Grisell Ortiz‐Lasanta, Mordechai Rabinovitz, David Bernstein, Michael Bennett, Trevor Hawkins, Natarajan Ravendhran, Aasim M. Sheikh, Peter Varunok, Kris V. Kowdley, Delphine Hennicken, Fiona McPhee, Khurram Rana, Eric A.

Metabolic and molecular responses to leucine‐enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis

Cynthia Tsien, Gangarao Davuluri, Dharmvir Singh, Allawy Allawy, Gabriella A.M. Ten Have, Samjhana Thapaliya, John M. Schulze, David Barnes, Arthur J. McCullough, Marielle P.K.J. Engelen, Nicolaas E.P. Deutz, Srinivasan Dasarathy – 22 January 2015 – Skeletal muscle loss (sarcopenia) is a major clinical complication in alcoholic cirrhosis with no effective therapy. Skeletal muscle autophagic proteolysis and myostatin expression (inhibitor of protein synthesis) are increased in cirrhosis and believed to contribute to anabolic resistance.

Safety of long‐term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection

Michele Barone, Antonella Notarnicola, Giuseppe Lopalco, Maria Teresa Viggiani, Francesco Sebastiani, Michele Covelli, Florenzo Iannone, Alfonso W. Avolio, Alfredo Di Leo, Luca Cantarini, Giovanni Lapadula – 22 January 2015 – European and Asian studies report conflicting data on the risk of hepatitis B virus (HBV) reactivation in rheumatologic patients with a previously resolved HBV (prHBV) infection undergoing long‐term biologic therapies. In this patient category, the safety of different immunosuppressive biologic therapies, including rituximab, was assessed.

Activation of aryl hydrocarbon receptor dissociates fatty liver from insulin resistance by inducing fibroblast growth factor 21

Peipei Lu, Jiong Yan, Ke Liu, Wojciech G. Garbacz, Pengcheng Wang, Meishu Xu, Xiaochao Ma, Wen Xie – 22 January 2015 – The aryl hydrocarbon receptor (AHR), also known as the dioxin receptor, was originally characterized as a xenobiotic receptor that senses xenotoxicants. We investigated the endobiotic and hepatic role of AHR in fatty liver and energy metabolism and identified the endocrine factor that mediates the metabolic function of AHR.

Subscribe to